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INTRODUCTION
BACKGROUND 
Global 
Cancers in all forms are causing about 12 per cent of deaths throughout the world. In 
the developed countries cancer is the second leading cause of death accounting for 
21% (2.5 million) of all mortality. In the developing countries cancer ranks third as a 
cause of death and accounts for 9.5% (3.8 million) of all deaths. Tobacco alcohol, 
infections and hormones contribute towards occurrence of common cancers all over 
the world.
India
Cancer has become one of the ten leading causes of death in India. It is estimated that 
there are nearly 1.5-2 million cancer cases at any given point of time. Over 7 lakh new 
cases of cancer and 3 lakh deaths occur annually due to cancer. Nearly 15 lakh 
patients require facilities for diagnosis, treatment and follow up at a given time. Data 
from population-based registries under National Cancer Registry Programme indicate 
that the leading sites of cancer are oral cavity, lungs, oesophagus and stomach 
amongst men and cervix, breast and oral cavity amongst women. Cancers namely 
those of oral and lungs in males, and cervix and breast in females account for over 
50% of all cancer deaths in India. 
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WHO has estimated that 91 per cent of oral cancers in South-East Asia are directly 
attributable to the use of tobacco and this is the leading cause of oral cavity and lung 
cancer in India.
Cancer usually occurs in the later years of life and with increase in life expectancy to 
more than 60 years, an estimate shows that the total cancer burden in India for all sites 
will increase from 7 lakh new cases per year to 14 lakh by 2026.
During the last decade, there has been a growing recognition of the high prevalence of 
fatigue among cancer patients, its adverse effect on their quality of life, and the need 
to develop effective interventions to prevent or relieve it. This increased attention can 
be attributed, in part, to the development of instruments for the assessment of fatigue 
and their validation with cancer patients. These instruments have provided researchers 
with the tools necessary for quantifying and characterizing fatigue and exploring its 
aetiology and treatment.
LACUNAE
As per the NCCN Survey conducted in July 2006 the following graphs actually denote 
the minimal awareness & serious lacunae in the Oncology speciality to deal with 
Cancer Related Fatigue & its effect on quality of life of patients.                     
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NCCN SURVEY ON TREATMENT OF FATIGUE – AWARENESS AMONG ONCOLOGIST
This study aims to address all these issues to bring about awareness and thus 
enabling better prophylactic and symptomatic interventions to correct the same.
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REVIEW OF THE 
LITERATURE
CANCER RELATED FATIGUE is a very important symptom that most of the cancer 
patients have either before, during or after the treatment. It will be discussed below 
under following headings:
• Definition 
• Significance
• Fatigue associated with cancer and its treatment
• Age & Cancer Related Fatigue
• Type of Cancer & Fatigue
• Causes
• The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with 
Quality of Life in Cancer
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DEFINING FATIGUE
A deﬁnition proposed by Cella and colleagues captures several of the more commonly 
described features of fatigue 2.
They deﬁne fatigue as, “a subjective state of overwhelming and sustained exhaustion 
and decreased capacity for physical and mental work that is not relieved by rest.” 
With regard to assess-ment, three features of this deﬁnition are worth noting. 
First, it identiﬁes fatigue as a subjective phenomenon, implying that it can best be 
measured via self-report methods. 
Second, it offers several ways in which fatigue may be distinguished from “nor-mal” 
tiredness. These include its severity and chronicity (“over-whelming and sustained 
exhaustion”) and its imperviousness to actions that typically provide relief from 
tiredness (“not relieved by rest”). 
Third, there is an implication as to the clinical significance of this phenomenon and its 
multidimensional qualities (“decreased capacity for physical and mental work”)
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SUMMARY: The assessment of fatigue in cancer patients is beset by a number of  
methodological challenges. The lack of a commonly agreed on deﬁnition of fatigue  
is perhaps the greatest challenge.
SIGNIFICANCE 
In a cross-sectional, questionnaire-based survey to investigate cancer patients' 
experience of fatigue and their perceptions about the causes, management and impact 
of this symptom at three regional cancer centres; Glasgow, Birmingham and 
Southampton 3  of  one thousand three hundred seven outpatients with cancer attending 
the three units over a 30-day period, the response rate was 576 of 1307 (44%). Fatigue 
was reported to affect 58% of patients 'somewhat or very much'. The comparable 
figures for pain and nausea/vomiting were 22% and 18%, respectively. Fatigue had 
never been reported to the hospital doctor by 52% (281 of 538) of patients with this 
symptom. Only 75 patients (14%) had received treatment or advice about the 
management of their fatigue. Fatigue was reported to be not well-managed by 33% 
(180 of 538) of patients with this symptom. The comparable figures for pain and 
nausea/vomiting were 9% (46 of 538) and 7% (37 of 538), respectively. The median 
FACT-F score was 18 (range 0-52). On multivariate analysis 54% of the variation in 
FACT-F scores could be explained by the combination of quality of life, depression, 
dyspnoea, weight loss/anorexia and use of analgesics in the previous month.
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CONCLUSIONS: Fatigue has been identified as an important problem by patients  
with cancer. It affects more patients for more of the time than any other symptom  
and is regarded by patients as being more important than either pain or  
nausea/vomiting. Research into the aetiology and management of this symptom  
should be regarded as a priority.
AGE & CANCER RELATED FATIGUE
Although fatigue has been a focus for research in adult cancer care for some time, the 
same cannot be said for adolescent oncology practice. Drawing on data from four 
empirical studies4, fatigue is multidimensional, multifactorial and highly subjective, 
but can be managed to enhance self-caring and coping strategies. All of the studies 
reviewed within indicate that fatigue is a troublesome symptom, which impacts on 
quality of life. From this review, we set up a research study. Concurring with the 
studies reviewed, findings from the preliminary data suggest that fatigue is a highly 
subjective and 'abnormal' phenomenon that holds a variety of implied meanings and 
associated metaphors connected with past experiences of childhood cancer. The focus 
group proved to be a viable research method to facilitate mutual disclosure and 
provoke discussion. Recognition of the research challenges with adolescents, where 
there is the potential for a range of meanings for the experience of fatigue, is an 
important finding for future studies.
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In a study5 of seventy-seven consecutive cancer patients with different tumors age 60+ 
served by the senior adult oncology program of the H. Lee Moffitt Cancer Center, 
were enrolled in the study. Inclusion criteria were: (1) age >-60 years; (2) histological 
diagnosis of malignancy; (3) no major psychiatric or neurological disorder that could 
interfere with the competition of the measures; (4) ability to understand and to speak 
English.  Assessment  included  cognition,  function,  depression  and  fatigue.  The 
instruments included geriatric depression scale,  mini  mental  state  examination and 
fatigue symptom inventory. The study used a cross-sectional design.
 Fifty-six patients (72.7%) reported fatigue at the time of the assessment; seventy-six 
patients (99%) in the past week. Forty patients (52%) rated their average fatigue as 
greater than 5. Forty-two patients (54%) reported that they felt fatigue all seven days, 
for any part of the day in the week before the assessment. Sixty five (84%) patients 
rated fatigue as interfering with their general level of activity. The fatigue 
disruptiveness was higher for women than for man (P<0.007). Marital status and 
educational level were not significantly related to fatigue severity or fatigue 
disruptiveness (P> or =0.33). A significant positive correlation between depressive 
symptoms and fatigue severity (r = 0.29, P<0.01) was recorded. Depression was also 
significantly related to fatigue disruptiveness (r = 0.44, P<0.01). Cognitive status was 
not correlated with fatigue severity or fatigue disruptiveness. A negative correlation 
between haemoglobin level and fatigue severity (r = -0.30, P<0.01) and between 
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haemoglobin level and fatigue disruptiveness (r = -0.28, P<0.01) was found. Having 
had medical care or counselling in the past for anxiety and depression was positively 
correlated with fatigue disruptiveness (r = 0.29, P<0.01).
CONCLUSION: Fatigue is a common symptom of older & adolescent cancer  
patients on  treatment.
TYPE OF CANCER & FATIGUE
BREAST CANCER6 
In a literature review6 to evaluate the prevalence and course of fatigue in patients 
with breast cancer undergoing adjuvant chemotherapy and to examine factors 
relating to fatigue, fatigue was one of the most common side effects of cancer 
treatment. 
High and fluctuating prevalence rates of fatigue have been found not only during 
but also after adjuvant chemotherapy. The intensity of fatigue seems to be stable 
throughout the treatment cycles, despite the common perception that more 
chemotherapy treatments lead to greater fatigue.
OVARIAN CANCER7
Although fatigue is a commonly reported symptom in cancer patients it is rarely 
investigated, especially in patients with ovarian carcinoma. 
Ninety-eight ovarian carcinoma survivors (average age of 57.4 +/- 12.5 years) were 
included in the study. All women had received cancer therapy but had not been treated 
for at least 6 months. The average time elapsed since first diagnosis was 5.7 +/- 5.5 
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years. Fatigue was measured with the Multidimensional Fatigue Inventory (MFI-20) 
and QOL was measured with the Functional Assessment of Cancer Therapy (FACT)-
ovarian carcinoma part and the European Organization for Research and Treatment of 
Cancer Care Questionnaire, including the ovarian carcinoma module.
 Thirty-two of 98 ovarian carcinoma patients (32.7%, 95% confidence interval, 23.5-
42.9%) reported MFI-20 General Fatigue scores >/= 12.0 and therefore could be 
characterized as suffering from fatigue. This group of patients had a significantly 
lower QOL, had higher scores of anxiety and depression, and perceived that they had 
less social support. In a multiple regression model, mental adjustment, social support, 
anxiety, and depression as well as fatigue were significant predictors of QOL (FACT-
generic part total score) whereas clinical and sociodemographic variables were not. 
A remarkably high proportion of ovarian carcinoma survivors suffered from fatigue. 
Because this symptom is a key predictor of QOL, it should be given more attention in 
aftercare programs.
Among 287 epithelial ovarian cancer survivors treated according to protocols at The 
Norwegian Radium Hospital between 1977 and 2003, 189 patients (66%) participated. 
Information was collected by a questionnaire containing demographic and morbidity 
items and self-rating scales. Internal comparisons of various subgroups of epithelial 
ovarian cancer survivors were performed, and epithelial ovarian cancer survivors 
were compared with age-adjusted controls from the general population. 
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Minimal differences were observed relating to somatic and mental morbidity, fatigue, 
and QOL between epithelial ovarian cancer survivors with and without relapse, long 
or short follow-up time, and prognostic index status. Chronic fatigue was found in 
22% (95% CI, 16% to 28%), and only body image was significantly associated with 
chronic fatigue in multivariable analyses. Epithelial ovarian cancer survivors showed 
significantly more somatic and mental morbidity, somatic complaints, use of 
medications, and use of health care services than controls. The levels of anxiety and 
fatigue were also significantly higher in epithelial ovarian cancer survivors than in 
controls, whereas the levels of depression and of several QOL dimensions were lower. 
The prevalence of chronic fatigue was 12% among controls. 
Epithelial ovarian cancer survivors had more somatic and mental morbidity, more 
fatigue, poorer QOL, and used more medication and health services than controls. 
Minimal differences were observed between various epithelial ovarian cancer 
survivors subgroups. Health care professionals should try to improve and be attentive 
to the health of epithelial ovarian cancer survivors.
HAEMATOLOGICAL MALIGNANCIES 8
In a study to describe fatigue severity, fatigue interference, and associated factors in 
hematologic malignancies. 
Patients being treated for leukemia and non-Hodgkin's lymphoma (n = 228) 
completed the Brief Fatigue Inventory to rate fatigue severity and functional 
interference caused by fatigue. Data on patient demographics, Eastern Cooperative 
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Oncology Group performance status, other physical symptoms, current treatments, 
and laboratory values were also collected. Descriptive statistics, bivariate correlation, 
and logistic regression were used for data analysis. 
Fifty percent of the sample reported severe fatigue, which was defined as a "fatigue 
worst" rating of 7 or greater. More patients with acute leukemia (61%) reported severe 
fatigue compared with those with chronic leukemia (47%) and non-Hodgkin's 
lymphoma (46%). Increased fatigue severity significantly compromised patients' 
general activity, work, enjoyment of life, mood, walking, and relationships with 
others. Fatigue severity was strongly associated with performance status, use of 
opioids, blood transfusions, gastrointestinal symptoms, and sleep disturbance items, as 
well as with low serum hemoglobin and albumin levels. Regression analysis indicated 
that nausea was the significant clinical predictor of severe fatigue (odds ratio, 13), and 
low serum albumin was the significant laboratory value predictor (odds ratio, 3.8). 
Disabling fatigue occurs with high frequency in hematologic malignancy, supporting a 
need to develop better methods of fatigue management. Better control of 
gastrointestinal and other symptoms may be of benefit. The mechanism and 
relationship between low albumin and severe fatigue needs to be investigated further, 
and longitudinal studies of the effects of treatment, host factors, and other symptoms 
are needed.
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LUNG CANCER 9
The medical records of 50 consecutive patients receiving radiation therapy for 
histologically diagnosed lung cancer were retrospectively reviewed to determine the 
frequency of fatigue and its relationship to pain, depression, and other potentially 
treatable correlates.
Fatigue developed in 39 of the 50 patients (78%), and was not strongly related to 
demographic or disease variables. Pain was experienced by 40 patients (80%), but 
depression was noted in the records of only six patients (12%). Onset of fatigue 
closely followed development of pain in only 11 patients. Lower frequency of fatigue 
in patients with previous surgery or chemotherapy and the likelihood of a response 
shift suggest these were not significant causes of fatigue. Previous studies highlight a 
higher frequency of depression in cancer patients and a correlation with treatment-
related fatigue. Prospective studies on the relationship between depression and fatigue 
and the ability of antidepressants to ameliorate treatment-related fatigue are needed.
In 573 advanced non-small-cell lung cancer patients enrolled in a phase III clinical 
trial 10, who used baseline and 6-week follow-up PRH scores to predict best response 
to treatment, disease progression, and survival. Using regression analyses, when tested 
the predictive ability of the five subscales of the Functional Assessment of Cancer 
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Therapy-Lung (physical, functional, social/family, emotional well-being, and the lung 
cancer subscale) as well as the trial outcome index (TOI) aggregate score.
After clinical factors were controlled for, baseline physical well-being (PWB) and 
TOI scores predicted all three clinical outcomes. A higher baseline PWB score was 
associated with a better response to treatment (odds ratio, 1.09; P <.001) and lower 
risk of death (risk ratio, 0.95; P <.001). Higher baseline TOI score was associated with 
a lower risk of disease progression (risk ratio, 0.98; P <.001). These two baseline 
predictors (PWB and TOI) were then used along with 6-week change scores to 
classify patients into four groups: low baseline-declined, low baseline-improved, high 
baseline-declined and high baseline-improved. Patients with low baseline-declined 
PWB scores showed the worst responses to treatment and survived the shortest 
duration. Patients with low baseline-declined TOI scores had the shortest time to 
progression. 
The physical aspects of baseline PRH and PRH change during chemotherapy are 
significant predictors of clinical outcomes in lung cancer. This has implications for 
patient stratification in clinical trials and may aid decision-making in clinical practice.
INCURABLE CANCER ? 11
The suffering of patients with incurable cancer is determined to a large degree by the 
presence and intensity of the symptoms of their disease. Knowledge of symptom 
prevalence is important for clinical practice. The main aim of this study was to obtain 
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a reliable estimation of symptom prevalence in patients with incurable cancer by 
performing a systematic review of studies assessing this topic. 
44 studies (including 25,074 patients) on overall symptom prevalence (Group 1) and 
six studies (including 2,219 patients) on symptom prevalence during the last one to 
two weeks of life (Group 2). In these studies, symptom prevalence was assessed by a 
questionnaire, a standardized interview, or the medical record. 37 symptoms assessed 
in at least five studies were identified. 
Almost all symptoms occurred in more than 10% of the patients. Five symptoms 
(fatigue, pain, lack of energy, weakness, and appetite loss) occurred in more than 50% 
of the patients of Group 1. Weight loss occurred significantly more often in Group 2 
compared to Group 1, and pain, nausea, and urinary symptoms occurred significantly 
less often. Generally, symptom prevalence was highest if assessed by a questionnaire. 
The results of this study should be used to guide doctors and nurses in symptom 
management. Proper attention to symptom burden and suffering should be the basis 
for individually tailored treatment aimed at improving or maintaining quality of life of 
patients in their last period of life.
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Conclusion: Fatigue is present in all cancer patients to varying degree irrespective  
of the site and histopathology
Fatigue associated with cancer and its treatment
In a study 12 designed to confirm the prevalence and duration of fatigue in the cancer 
population and to assess its physical, mental, social, and economic impacts on the 
lives of patients and caregivers. A 25-minute telephone interview was completed with 
379 cancer patients having a prior history of chemotherapy. Patients were recruited 
from a sample of 6, 125 households in the United States identified as having a 
member with cancer. The median patient age was 62 years, and 79% of respondents 
were women. Patients reporting fatigue at least a few times a month were asked a 
series of questions to better describe their fatigue and its impact on quality of life. 
Seventy-six percent of patients experienced fatigue at least a few days each month 
during their most recent chemotherapy; 30% experienced fatigue on a daily basis. 
Ninety-one percent of those who experienced fatigue reported that it prevented a 
"normal" life, and 88% indicated that fatigue caused an alteration in their daily 
routine. Fatigue made it more difficult to participate in social activities and perform 
typical cognitive tasks. Of the 177 patients who were employed, 75% changed their 
employment status as a result of fatigue. Furthermore, 65% of patients indicated that 
their fatigue resulted in their caregivers taking at least one day (mean, 4.5 days) off 
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work in a typical month. Physicians were the health care professionals most 
commonly consulted (79%) to discuss fatigue. Bed rest/ relaxation was the most 
common treatment recommendation (37%); 40% of patients were not offered any 
recommendations. 
Cancer-related fatigue is common among cancer patients who have received 
chemotherapy and results in substantial adverse physical, psychosocial, and economic 
consequences for both patients and caregivers. Given the impact of fatigue, treatment 
options should be routinely considered in the care of patients with cancer.
Fatigue is often related to cancer, and that related to its treatment is the most 
commonly reported side effect of cancer treatment. It differs from that induced by 
other causes, such as sleep disturbance and exertion, as the latter are typically 
alleviated by a period of rest. In contrast to exercise-induced fatigue, the fatigue 
reported by cancer patients is usually described as an unusual, excessive, whole-body 
experience that is disproportionate or unrelated to activity or exertion and is not 
relieved by rest or sleep. Cancer-related fatigue is a subjective experience that has a 
clear detrimental effect on a cancer patient's quality of life and ability to sustain the 
usual personal, professional, and social relationships. The fatigue can be pervasive: 
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cancer patients frequently report that fatigue begins with treatment, continues during 
the course of chemotherapy or radiation treatment, and declines somewhat - but 
frequently sustains at a higher-than-baseline rate - after treatment is over. It may also 
persist for several years even in patients with no apparent disease. While a number of 
researchers have speculated about the nature of cancer-related fatigue, there has been 
little systematic research on its etiology or treatment. In many aspects our knowledge 
of the fatigue mechanisms in cancer patients is at a similar stage to that reached in our 
understanding of anti-cancer therapy-induced nausea and vomiting about 20 years 
ago. This paper introduces four plausible hypotheses for the development of fatigue. 
Evidence available to support a role for anemia, adenosine triphosphate, vagal 
afferents, and the interaction of the HPA/cytokines and 5HT is discussed.13
A study 14 was conducted to assess symptom prevalence and symptom intensity and 
their relation to quality of life in medical oncology patients at a Veterans Affairs 
medical center. 
Consecutive inpatients and outpatients were asked to complete the Functional 
Assessment Cancer Therapy (FACT-G), Memorial Symptom Assessment Scale 
(MSAS), and the Brief Pain Inventory. Symptoms then were analyzed by their relation 
to Karnofsky performance status (KPS) and quality of life. 
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 Two hundred forty patients participated. The median number of symptoms was 8 per 
patient (range, 0-30 symptoms). The 5 most prevalent symptoms were lack of energy 
(62%), pain (59%), dry mouth (54%), shortness of breath (50%), and difficulty 
sleeping (45%). Patients with moderate intensity pain had a median number of 11 
symptoms and patients with moderate intensity lack of energy had a median number 
of 13 symptoms. The number of intense symptoms increased as the KPS decreased (P 
< 0.001). Patients with moderately intense pain or fatigue also were more likely to 
experience nausea, dyspnea, and lack of appetite. The number of symptoms rated as 
present on the Memorial Symptom Assessment Scale was found to correlate 
significantly with the FACT-G Sum Quality of Life score. 
Intense symptoms were highly prevalent in this population. The presence of pain, lack 
of energy, or poor performance status should lead to comprehensive symptom 
assessment. Patients free of disease nevertheless still may experience intense 
symptoms. The number of symptoms present may be a helpful guide to quality of life. 
Routine comprehensive symptom assessment may identify a significant fraction of 
patients who urgently require intensive symptom palliation.
Cancer patients undergoing radiotherapy frequently report fatigue 15. However, 
knowledge of the importance of fatigue for these patients and of the factors associated 
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with their fatigue is limited. The aim of the current investigation was to gain more 
insight into fatigue as related to radiotherapy by answering the following questions.
First, how is the experience of fatigue best described? Secondly, to what extent is 
fatigue related to sociodemographic, medical (including treatment), physical and 
psychological factors? Finally, is it possible to predict which patients will suffer from 
fatigue after completion of radiotherapy? Patients with different types of cancer 
receiving radiotherapy with curative intent (n = 250) were interviewed before and 
within 2 weeks of completion of radiotherapy. 
During treatment, patients rated their fatigue at 2-weekly intervals. Results indicate a 
gradual increase in fatigue over the period of radiotherapy and a decrease after 
completion of treatment. Fatigue scores obtained after radiotherapy were only slightly, 
although significantly, higher than pretreatment scores. 
After treatment, 46% of the patients reported fatigue among the three symptoms that 
caused them most distress. Significant associations were found between post-
treatment fatigue and diagnosis, physical distress, functional disability, quality of 
sleep, psychological distress and depression. No association was found between 
fatigue and treatment or personality characteristics. Multivariate regression analysis 
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demonstrated that the intensity of pretreatment fatigue was the best predictor of 
fatigue after treatment. In view of this finding, a regression analysis was performed to 
gain more insight into the variables predicting pretreatment fatigue. The degree of 
functional disability and impaired quality of sleep were found to explain 38% of the 
variance in fatigue before starting radiotherapy. Fatigue in disease-free patients 9 
months after treatment was observed.
Although studies show that cancer patients consider fatigue as an important problem, 
few, if any, studies have quantified the impact of fatigue on overall quality of life 
(QoL) in cancer patients. In recent study, evaluation of the relative impact of different 
QoL domains/subscales, including fatigue, on overall QoL in cancer patients 
preceding radiotherapy was done 16. 
Sixty-four patients with lung or breast cancer selected for high-dose radiotherapy on 
the primary tumour completed the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire. Multivariate models were fitted to define the 
impact of QLQ-C30 subscales, including fatigue, on overall QoL. 
Of all QLQ-C30 subscales, fatigue showed by far the strongest univariate correlation 
with overall QoL (r = -0.76, P < 0.001); correlations for functioning subscales (r = 
0.44-0.55) and symptom subscales (r = -0.31 to -0.45) were considerably lower. In 
multivariate analyses, adjusting for potential confounders, fatigue was the only 
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subscale that independently contributed to overall QoL (standardized regression 
coefficient-0.57, P < 0.001). 
Results indicated that, of all QoL domains/subscales, fatigue is by far the predominant 
contributor to patient-perceived overall QoL in both lung and breast cancer patients 
preceding high-dose radiotherapy.
Causes of Fatigue
The specific mechanisms involved in the development of cancer related fatigue 
are not completely known. Various factors play a part in the development of Fatigue. 
Several studies have reported different mechanisms and causes of Fatigue but only 
few of them are proven. 
The causes of fatigue can be broadly divided into
Nutrition and metabolism
Medications
Co-morbid conditions
Psychosocial and Cognitive factors
Cancer therapies
Nutrition and metabolism
The nutritional  requirements  and  metabolism are  altered  in  cancer  patients. 
There  is  decreased  availability  of  metabolic  substrates  due  to  increased  energy 
demand  by  the  normal  tissues  for  fighting  against  the  growing  tumor.  Tumor 
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consumption of available nutrients, hypermetabolic condition due to tumor growth, 
associated  infections  and  fever  result  in  increased energy requirements.  Moreover 
there  is  also  reduced  energy  support  due  to  cancer  cachexia,  nausea,  vomiting,  
diarrhea  and  intestinal  malabsorption.  Due  to  all  these  factors  there  is  impaired 
glucose, lipid and protein metabolism which ultimately results in abnormal production 
of  substances  (eg.  cytokines  or  antibodies).   These  inhibit  metabolism or  normal 
muscle function, cause neurophysiologic changes of skeletal muscles, chronic stress 
response and hormonal changes. One very important factor which has been proven to 
directly  affect  fatigue is  anemia.  Anemia may be caused directly  by the impaired 
nutrition or disease itself or Myelosuppression due to treatment itself.
Medications
Drugs  other  than  chemotherapeutic  agents  like  analgesics,  antiemetics, 
antidepressants,  anti  histaminics,  cough  suppressants  and  antacids  which  have 
sedative effects (either as main or side effect) invariably contribute to fatigue.
Co morbid conditions
Other co-morbid conditions which may be present like infections, dehydration, 
lung diseases, liver failure, cardiac diseases, renal failure thyroid disorders also add to 
the fatigue 
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Psychosocial and Cognitive factors
Most of the cancer patients are very anxious about the outcome of the disease 
and  treatment.  There  is  also  associated  depression,  stress,  mental  fogginess  and 
decreased attention span. Because of all these there is sleep disturbances also which 
put together causes fatigue. The cancer patients withdraw themselves from the social  
interaction due to the diagnosis of cancer and its treatment.
Cancer therapies13,14,15,16
Several factors may place the surgical patient at risk of fatigue. These include 
the  effects  of  anaesthesia,  analgesia,  and  sedation,  decreased  ventilatary  capacity,  
immobilization, infection, pre and post operative starvation, altered sleep patterns and 
anxiety.  Fatigue after surgery may be compounded in cancer patients  who receive 
adjuvant treatment, as they have often not recovered their energy levels before starting 
further treatment.
The way by which chemotherapy affects fatigue has not been fully understood. 
Many chemotherapy regimens (especially  platinum based drugs)  cause  cumulative 
anemia,  resulting  in  decreased  oxygen  supply.  Also  patients  can  also  develop 
neutropenia  and  infection  which  may  result  in  fatigue.  Some  drugs  (bleomycin,  
adriamycin,  BCNU,  epirubicin,  mitozantrone  and  mitomycin)  may  cause  cardiac 
toxicities,  neurotoxicities  (methotrexate,  ifosphamide,cisplatin,  vincristine, 
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paclitaxol). It has also been noted that patients treated with biological therapies like  
interferon, interlukin, colony stimulating factors and tumor necrosis factor experience 
fatigue. In several studies fatigue is the most frequently reported dose limiting toxicity 
of biological therapy and has caused patients to refuse further treatment.
It is not known how radiotherapy causes fatigue. However it may be associated 
with increased energy needed to repair damaged epithelial tissue caused by radiation.
Summary: Fatigue is caused due to nutritional and metabolic impairment,  
associated co morbid condition, and medications, psychosocial factors and also due  
to treatment modalities.
FATIGUE & QUALITY OF LIFE 
Fatigue affects a majority of patients undergoing cancer-related therapies. 
A study of 954 adult cancer patients was conducted between April 2001 and 
November 2004 to quantify the relationship between fatigue and patient satisfaction 
with quality of life (QoL)17. 
Fatigue was measured using the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire fatigue subscale. 
Patient satisfaction with QoL was measured using the Ferrans and Powers Quality of 
Life Index (QLI). 
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The relationship between fatigue and QLI was evaluated using univariate and 
multivariate linear regression after controlling for the effects of clinical and 
demographic factors. Of the 954 patients, 579 were females and 375 males, with a 
median age at presentation of 56 years (range 20-90 years). Sixty-six percent had 
failed prior treatment. The most common cancers were breast (26%), colorectal 
(19%), and lung (16%) cancers. 
After controlling for the effects of age and prior treatment history, every 10-unit 
increase in fatigue was statistically significantly associated with 1.5-, 0.22-, 0.77-, 
0.27-, and 0.85-unit declines in QLI health and physical, social and economic, 
psychological and spiritual, family, and global function scores, respectively. 
Consequently, a 30-point increase in fatigue score correlates with a 4.5-point decline 
in QLI health functioning-a clinically significant decline. 
The impact of fatigue on the quality of life of oncology patients is substantial and 
under-recognized. Fatigue in these patients may begin with a simple decrease in 
physical activity, but can progress to include a wide range of negative effects that 
often culminate in patients feeling out of control, lonely, and isolated. In general, 
surviving cancer patients experience some limitations after the end of treatment but 
ultimately attain a reasonably good level of functioning. 
34 | P a g e  
An examination of subpopulations and further analyses of data suggest, however, four 
different recovery patterns 18. 
Patients may: 
A) improve in their functioning, reach a plateau at approximately year 2 or 3, and then 
remain at relatively high levels of functioning; 
B) improve initially, but deteriorate again after year 2 or 3, never reaching the normal 
stage; 
C) improve, returning to normal; or 
D) have a very mixed pattern of high levels of fatigue that is, to date, very difficult to 
interpret. 
Disturbingly, 60% of the survivors in our population of patients with Hodgkin's 
disease, who were treated in recent trials of the German Hodgkin Study Group and the 
European Organization for Research and Treatment of Cancer Lymphoma Group, had 
medium to high levels of fatigue after 5 cancer-free years. Investigations are essential 
to determine the current status of long-term survivors in more detail and to link that 
status to conditions observed during the treatment of acutely ill patients.
Data obtained from one academic hospital and two general hospitals in the 
Netherlands 19. 235 patients who had a primary diagnosis of cancer and underwent 
treatment with curative intent were included. The rate of return to work was measured 
at 6, 12 and 18 months. Hazard ratios (HRs) for the duration of sick leave up to 18 
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months following the first day of sick leave were calculated. The rate of return to 
work increased from 24% at 6 months to 64% at 18 months following the first day of 
sick leave. Fatigue, diagnosis, treatment type, age, gender, depression, physical 
complaints and workload were all related to the time taken to return to work. Fatigue 
scores were also strongly related to diagnosis, physical complaints, and depression 
scores. Fatigue at 6 months predicted a longer sick leave with a hazard ratio of 0.71 
(95% Confidence Interval (C.I.) 0.59-0.85), adjusted for diagnosis, treatment type, age 
and gender. In a multivariate Cox regression analysis, diagnosis, treatment, age, 
physical complaints and workload remained the only significant predictors of duration 
of the sick leave. 64% of cancer survivors returned to work within 18 months. Fatigue 
levels predicted the return to work. This was independent of the diagnosis and 
treatment, but not of other cancer-related symptoms. Better management of cancer-
related symptoms is therefore needed to facilitate the return to work of cancer 
patients.
A study 20 was evaluated whether diagnostic criteria for cancer-related fatigue 
syndrome (CRFS) could be rigorously applied to cancer inpatients, and to explore the 
relationship between subjective fatigue and objective measures of physical activity, 
sleep, and circadian rhythm. Female cancer patients (n=25) and a comparison group of 
subjects without cancer (n=25) were studied. Study participants completed a 
structured interview for CRFS and questionnaires relating to fatigue, psychological 
symptoms, and quality of life (QoL). Wrist actigraphs worn for 72 hours were used as 
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an objective measure of activity, sleep, and circadian rhythm. Compared to controls, 
cancer patients were more fatigued, had worse sleep quality, more disrupted circadian 
rhythms, lower daytime activity levels, and worse QoL. After exclusion of subjects 
with "probable" mood disorders, the prevalence of CRFS was 56%. Fatigue severity 
among the cancer patients was significantly correlated with low QoL, depression, 
constipation, and decreased self-reported physical functioning. It can be concluded 
that the diagnostic criteria for CRFS can be applied to cancer inpatients but strict 
application requires a rigorous assessment of psychiatric comorbidity. Despite cancer 
inpatients having greater impairments of sleep and circadian rhythm, it was found that 
fatigue severity did not appear to be related to these impairments.
EVALUATION OF FATIGUE & QOL 
UNIDIMENSIONAL AND MULTIDIMENSIONAL MEASURES OF FATIGUE
In the absence of a commonly agreed on deﬁnition of fatigue, it is not surprising that 
there is a lack of consensus about the optimal approach to assessing fatigue in cancer 
patients. Although the importance of obtaining patient self-reports is widely
acknowledged, a variety of self-report instruments are currently in use. Much of the 
time, fatigue is assessed using a single item embedded in a symptom checklist such as 
the Symptom Distress Scale 21 or the Rotterdam Symptom Checklist  22. 
Single-item visual analog scales and Likert-type scales are also often used to assess 
fatigue. Because of their single-item format, these measures have limited reliability 
and provide only the most perfunctory information about patients’ experiences with 
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fatigue. Fatigue is also often assessed using multi-item measures such as the Fatigue 
Scale of the Proﬁle of Mood States 23. Although these multi-item measures generally 
possess better psychometric properties than single-item measures, most are limited in 
that they provide information only about a patient’s general level of fatigue severity.
In a more comprehensive approach, several investigators have developed and 
validated multidimensional measures of fatigue for use with cancer patients. Such 
measures include the Brief Fatigue Inventory 24, the Revised Piper Fatigue Scale 25,
the Cancer Fatigue Scale 26, the Revised Schwartz CancerFatigue Scale 27, the 
Multidimensional Fatigue Inventory 28,and the Multidimensional Fatigue Symptom 
Inventory 29. A recent publication provides information about the format of
these and other measures and summarizes their psychometric properties 30. Inspection 
of these measures indicates that there is little consensus at this time about the 
dimensional structure of fatigue in cancer patients (see Table 1). For example, one
measure characterizes fatigue in terms of general, mental, and physical dimensions31, 
whereas another measure characterizes it in terms of behavioral/severity, affective 
meaning, sensory, and cognitive/mood dimensions .The Fatigue Symptom Inventory 
(FSI), a measure developed by a research group for the multidimensional assessment 
of fatigue. The FSI is a 14-item measure that assesses the severity,
frequency, and diurnal variation of fatigue, as well as its per-ceived interference with 
quality of life. Severity is measured using four separate items that assess most, least, 
and average fatigue in the past week as well as current fatigue.
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Frequency is measured using two separate items that assess the number of days in the 
past week that respondents felt fatigued as well as the portion of each day on average 
they felt fatigued. Diurnal variation is measured using a single item that provides
descriptive information about daily patterns of fatigue. Perceived interference is 
measured using seven separate items that assess the degree to which fatigue in the past 
week was judged to interfere with general level of activity, ability to bathe and
dress, normal work activity, ability to concentrate, relations with others, enjoyment of 
life, and mood. The interference ratings can also be summed to yield a total 
interference score. Preliminary evidence of the reliability and validity of the FSI has 
been reported for women with breast cancer  and for men and women with a variety of 
cancer diagnoses .
 
QUALITY OF LIFE 
1. FACT -  The Functional Assessment of Cancer Therapy - consists of the FACT-G
2. European Organization for Research and Treatment 
of  Cancer  QOL  Questionnaire —  The  European 
Organization  for  Research  and  Treatment  of  Cancer 
Quality of Life Questionnaire - EORTC OLQ-C30 [.  This scale includes items 
assessing  symptoms and side  effects  ,  and appears  to  be  sensitive  to  temporal 
TABLE 1
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changes before, during and after treatment with surgery, radiation therapy (RT), 
and chemotherapy
3. University  of  Washington  Quality  of  Life — The  University  of  Washington 
Quality of Life (UW-QOL) questionnaire is a self-administered scale consisting of 
15 questions assessing nine domains including pain, physical appearance, activity, 
recreation,  employment,  chewing,  swallowing,  speech,  shoulder  function,  and 
overall  QOL.  One  study  of  29  patients  undergoing  resection  of  oral  cancer 
compared the EORTC QLQ H & N35 with the UW-QOL. The two scales were 
found to be complementary rather than duplicative. The authors concluded that 
although the UW-QOL provided less specific information compared to the EORTC 
QLQ H & N35, it was shorter and easier to use.
4. Quality of Life Radiation Therapy Instrument — A head and neck module has 
been developed for the quality of life - radiation therapy instrument (QOL-RTI)
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 AIMS AND OBJECTIVES
 To determine the magnitude of fatigue in Cancer Patients
 To determine the effect of Cancer Treatment (Chemotherapy, Radiotherapy) 
on fatigue.
 To determine the effect of Fatigue on Quality of Life.
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 MATERIALS AND 
METHODS
DISCLOSURES
This study was done purely in the Government hospital after obtaining the consent 
from the involved patients. The Tamil consent form is attached (appendix II)
Ethical Committee clearance was obtained prior to the study.(appendix I)
The license required to use the FACT-G in this study was obtained (appendix IV)
The validity & reliability report for the FACT-G also obtained (appendix V)
The study was periodically reviewed & presented in the department during the course.
Estimation of Sample Size
The estimation of sample size is based on the study “Cancer-related fatigue: 
inevitable, unimportant and untreatable? Results of a multi-centre patient 
survey. Cancer Fatigue Forum.AU - Stone P et al”. The sample size is estimated 
based on 5% significance level and with an error of 0.6. The sample size required is 
110.
Sampling procedure
120 patients with histologically proven cancer, receiving Cancer Treatment in 
the Radiation Oncology department of Madras Medical College FEBRUARY 2009 to 
September 2009 were the subjects of the study.
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Inclusion criteria
 Patients above 15 years.
 Patient with histological documentation of Cancer.
 Patients receiving External Beam Radiotherapy or Chemotherapy.
 Patients with Karnofsky Performance Status(KPS) 70 and above 
Exclusion criteria
 Patients below 15 years.
 Patients with KPS<70
Data Collection
Common Toxicity Criteria –Fatigue, Functional Assessment of Cancer 
Treatment  - G , TAMIL version for Fatigue and Quality of Life respectively were 
used in this study. Answers to the questionnaires on fatigue and quality of life will be 
filled by all the patients of the study by means of personal interview, before start of 
treatment, every week during the treatment and one month post treatment. For patients 
who did not know to read and write, were explained about the questionnaire in their 
mother tongue and response noted by the person interviewing.
TABLE 2 
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                                            RESULTS
Statistical software: 
The Statistical software namely SPSS 11.0 and Systat 8.0 were used for the analysis of 
the data and Microsoft word and Excel have been used to generate graphs, tables etc.
MALE: FEMALE:
                                                           FIGURE 1
Of the 120 patients 30(25%) were females & 90 (75%) males (FIGURE 1)
AGE:
FIGURE  2
AGE FEMALES MALES
15-20 1 4
21-30 5 4
31-40 8 11
41-50 8 25
51-60 3 25
>60 5 21
TABLE  3
61 (50%) patients were between the age of 40-60 years.26 (18%) were above 60 years 
(FIGURE 2 & TABLE 3)
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SITE:
Figure 3
SITE N = 120
Head & Neck 51
BREAST 11
CERVIX 8
CNS 21
LUNG 10
GastroIntestinal 8
Genito-Urinary 4
LYMPHOMA 2
ALL 2
Metastasis of Unknown Origin 2
Soft Tissue Sarcoma 1
Table  4
TREATMENT POLICY:
FIGURE  4
POLICY N=120
PALLIATIVE 30
CURATIVE 90
TABLE 5
30(25%) patients underwent palliative treatment while 90(75%) Curative.
(Figure 4 & Table 5)
MODALITY:
Figure 5
45 | P a g e  
While a single modality of treatment is offered to early stage diseases (Stage I & II) , 
most of the patients who reported to our department were locally advanced cases 
(Stage III & IV) for whom combined modality of treatment is the treatment of choice.
16(14%) patients were treated with Radiotherapy only. Treatment being mostly 
palliative. 63(51%) patients were treated with Chemo-Radiotherapy.
41(33%) were treated with all the three arms of Surgery, Chemotherapy & 
Radiotherapy
FATIGUE:
Figure 6
As it is evident on the figure 6 most of the patients reported with a mild level of 
fatigue to begin with. 
Most importantly the majority of the conversion from mild to moderate & severe 
fatigue was during the 4th & 5th week of the treatment (p= <0.005)
Another important point to be noted is that 111(90%) never reached their pretreatment 
levels of fatigue, even at follow up
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FIGURE 7
The mean average scores for the Physical well being of the patients suggest that the 
physical well being was adversely affected as treatment continued.
Figure 8
The social wellbeing denoting the relationship of the patient with his surroundings, 
friends & family was adversely affected too with the mean average scores declining 
on the weekly basis.The scores improved during the follow up though. (p=0.15)
Figure 9
The ability of the patient to cope with one’s self was affected with the mean average 
scores declining as weeks of treatment progressed. The scores remained at the low 
levels even at follow up when the patient. This perhaps denotes very important criteria 
as the patient’s will to live & cope with life after being affected by cancer is a crucial 
factor.
Figure 10
The ability of the patient to get back to his/her normal daily activities & work as 
he/she performed prior to the disease is denoted by the Functional Well Being.This 
though declined as other parameters but was by far the only parameter to reach its 
almost pre-treatment levels.(p=0.05)
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Figure 11
Figure 12
Overall Quality of Life & its individual aspects were adversely affected as the 
treatment progressed as noted in the Figure 11 & Figure 12.The mean average scores 
did not reach the pre-treatment level scores even during the follow up.
Physical well being & Emotional Well Being were affected the most. Functional well 
being scores improved after treatment.
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    DISCUSSION
Despite the well-documented prevalence of fatigue in patients diagnosed with cancer, cancer-
related fatigue (CRF) remains a widely under-reported and under-treated phenomenon.  If 
advances in health care provision are to be successful in minimizing the suffering and distress 
caused by cancer-related fatigue an understanding of how people communicate its impact to 
family, friends, and healthcare professionals, and what meanings they ascribed to be, is essential. 
Although the word “fatigue” is understood by the scientific community it is unclear whether 
patients will spontaneously refer to their feeling of lack of energy, weakness, sleepiness, lack of 
motivation, desire for rest, etc. as “being fatigued.”
The purpose of this research was to draw on qualitative research to explore how 
patients with cancer-related fatigue describe it.
The most salient finding was that in most of the studies cancer-related fatigue was 
reported as being of greater intensity than previously experienced tiredness, 
contributing to the general feeling that cancer-related fatigue was ‘overwhelming’ as 
well as abnormal.  Furthermore, patients emphasized that cancer-related fatigue 
differed from their previous experiences of tiredness in its duration/persistence even 
after rest.  Although triggers could be identified by some patients (e.g., 
chemotherapy), others conveyed the fact that cancer-related fatigue’s unpredictability 
added to the frustration/despair and cognitive distress (e.g., inability to focus, inability 
to make decisions).  Patients also reported a lack of motivation for engaging in 
activities with friends or family and a preference for staying by themselves to rest.
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This study mainly aims to answer one most important question of all & in the end 
poses a question by itself.
IS CANCER RELATED FATIGUE REAL?
That is the question that this study answers with a resounding yes! & poses a 
challenge & a new question ,
IF IT IS A REAL SYMPTOM , THEN WHY NOTHING MUCH IS DONE ABOUT 
IT IN DAY TO DAY PRACTICE?
The answer lies probably in the literature about the various options available for the 
treatment of Cancer related Fatigue.
Review of Treatment Options 
INTERVENTIONS — Management of cancer-related fatigue involves specific 
treatment for potentially reversible causes (ie, treating anemia or metabolic or 
endocrine abnormalities, as well as managing pain, insomnia, depression, or anxiety) 
and symptomatic measures when no obvious etiology or reversible cause can be 
identified. Nonspecific symptomatic treatment measures include education, 
counseling, and pharmacologic (eg, psychostimulants) as well as nonpharmacologic 
(eg, exercise, yoga, acupuncture) measures.
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Management of anemia — Anemia is the most common reversible cause of cancer-
related fatigue, particularly among patients receiving chemotherapy. Optimal 
management of symptomatic anemia requires an accurate diagnosis to identify 
potentially remediable causes (eg, ongoing blood loss, hemolysis, iron, folic acid, or 
vitamin B12 deficiency). If a potentially treatable cause cannot be identified, 
treatment options include red blood cell (RBC) transfusion, or for patients with 
chemotherapy-related myelosuppression, an erythropoietin stimulating agent (ESA). 
ESAs — the efficacy of ESAs (epoetin alfa and darbepoetin alfa) was initially 
established in anemic patients with chronic renal failure on dialysis. These agents 
have been extensively evaluated in cancer patients. While numerous randomized trials 
demonstrate that ESAs decrease the frequency of RBC transfusion in patients 
receiving chemotherapy for a nonmyeloid cancer, their impact on fatigue has been 
more difficult to demonstrate due to the direct mediating effect of hemoglobin levels 
and the confounding effect of transfusions. However, the available data suggest that 
ESAs modestly improve symptoms of fatigue in anemic patients receiving 
chemotherapy.Four trials of darbepoetin in anemic cancer patients (three 
chemotherapy-related, one not chemotherapy-related) showed a borderline statistically 
significant improvement in fatigue score relative to placebo (SMD in fatigue score 
-0.13, 95% CI -0.27 to 0.00, p = 0.05). The impact of darbepoetin on cancer-related 
fatigue was further addressed in a compilation of data from the three placebo-
51 | P a g e  
controlled trials of patients receiving chemotherapy for lung cancer (two trials, 595 
and 314 patients each) or a lymphoproliferative malignancy (one trial, 349 patients) 32. 
Fatigue was measured using the FACT-F scale. 
Until recently, ESAs were heavily promoted and utilized in cancer patients who had 
fatigue and any degree of anemia, whether related to chemotherapy or not. However, 
use of these agents has become controversial, particularly in patients with anemia 
unrelated to chemotherapy and in those receiving myelosuppressive chemotherapy 
with the intent of cure, because of concerns about thromboembolic side effects, higher 
mortality rates, and the possibility of adverse cancer outcomes.
At least eight trials have shown inferior survival, worse locoregional tumor control, 
and/or increased risk of thromboemboli in solid tumor patients treated with ESAs. In 
all eight, ESA dosing was targeted to achieve and maintain hemoglobin levels in 
excess of current recommendations (≥ 12 g/dL); in four, patients were receiving 
adjuvant or neoadjuvant chemotherapy for a potentially curable cancer, and in three, 
ESAs were administered to patients not receiving chemotherapy. These data led the 
US Food and Drug Administration to mandate labeling changes for ESAs that state 
that they are not indicated in patients with non-chemotherapy-related anemia or for 
those receiving myelosuppressive chemotherapy when the anticipated outcome is 
cure. The risks of shortened survival and inferior tumor control have neither been 
excluded nor confirmed when ESAs are dosed to a target hemoglobin <12 g/dL, the 
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level supported by ASCO/ASH and NCCN guidelines . Nevertheless, all three groups 
recommend that ESAs NOT be used for cancer patients with anemia not associated 
with chemotherapy, that ESAs not be instituted unless the hemoglobin level is ≤ 10 
g/dL, and that target hemoglobin levels not exceed 12 g/dL 33 . 
The above data relate to patients being treated for a nonmyeloid malignancy. The use 
of ESAs in patients with hematologic neoplasms is more complex. Although 
thromboembolic events and adverse cancer outcomes have not been reported, there is 
less evidence to support benefit from ESAs, responsiveness of the bone marrow may 
be compromised in these settings, and there are persisting concerns as to the 
possibility of stimulating clonal growth with hematopoietic growth factors.
Cognitive-behavioral and psychosocial interventions — Ideally, information about 
the expected pattern and duration of fatigue should be offered to patients before they 
start treatment with chemotherapy, high-risk molecularly-targeted compounds, 
radiation therapy (RT), or biologic response modifiers. Randomized trials and a meta-
analysis indicate that a variety of nonpharmacologic psychoeducation interventions 
are effective for improving cancer-related fatigue34,35,36,37,38,39, and its benefits have 
been shown to persist for at least two years after intervention . However, whether all 
patients require formal cognitive behavioral therapy (CBT) by a psychologist or 
psychiatrist is unclear.
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The benefit of a defined program of energy conservation and activity management 
(ECAM) was shown in a trial in which 396 cancer patients beginning chemotherapy, 
radiation, or both were randomly assigned to a semistructured, customized ECAM 
intervention (focusing on specific strategies and methods to conserve energy) 
administered by nurses or a control group, for whom a similar amount of nursing time 
and attention was focused on diet and nutrition . Individuals who received the ECAM 
intervention had a significantly greater decrease in fatigue over time compared to the 
control group; however, this did not translate into improved overall functional 
performance.
To the extent that fatigue has a physiologic basis, cognitive-behavioral interventions 
may not be effective in all patients. In a randomized study that included 115 patients 
receiving radiation therapy for advanced cancer, a structured multidisciplinary 
program that included cognitive, emotional, physical, social, and spiritual 
interventions did not prevent the development of fatigue 39 , even though it was 
associated with an improvement in quality of life 40.
The challenge to the practitioner is to match the characteristics of individual patients 
with the most helpful and cost-effective interventions.
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Exercise — To avoid fatigue, cancer patients often are advised to rest and 
downregulate their daily activities. However, because inactivity can induce muscular 
wasting, prolonged rest can lead to further loss of physical strength and endurance41. 
Although many fatigued patients have difficulty believing that exercise will improve 
their symptoms, physical exercise training programs can increase functional capacity, 
leading to reduced effort in performing usual activities and a decreased sense of 
fatigue42,43.
Research on the effects of exercise on cancer-related fatigue includes studies of 
patients receiving active treatment and those who have completed treatment. 
Experimental designs vary, sample sizes often are small, and many series are limited 
to women with breast cancer. The type of aerobic exercise is variable, with some 
studies evaluating walking, bicycling, resistance training , or a combined approach , 
and still others where the patient was allowed to choose the type of exercise he or she 
preferred . The recommended exercise programs vary in length from six weeks to six 
months.
Regardless of these limitations, all studies, as well as three comprehensive reviews on 
the benefits of exercise in patients with cancer44,45, demonstrate significant benefits for 
moderate exercise in patients with cancer. Patients who exercise during or after the 
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completion of treatment have significantly less fatigue and emotional distress, 
decreased sleep disturbance, improved functional capacity, and better QOL compared 
to those who do not. 
Sleep therapy — Sleep disturbance associated with fatigue is often difficult to treat 
and manage. It may be influenced by numerous factors including daytime naps, 
depression, anxiety, medication, sleep interruption because of nocturia or hot flashes, 
and evening food and/or beverage intake.
Although sleep disturbance is common in patients with cancer, few studies have 
evaluated sleep interventions to manage fatigue: In a pilot study of 25 women 
receiving adjuvant chemotherapy for breast cancer, stimulus control (ie, having a 
consistent time to lie down and get up, avoiding caffeine and stimulating activity in 
the evening) and sleep restriction (ie, avoiding long or late-afternoon naps, limiting 
time in bed to the normal hours of sleep only) significantly improved fatigue46. 
Benefit from a multimodality sleep hygiene program was suggested in a controlled 
study of two different relaxation techniques for up to six months47. Compared to the 
control group, both intervention groups had significantly better sleep latency, sleep 
duration, and daytime functioning. 
Acupuncture — A possible benefit from acupuncture was suggested in a randomized 
phase II trial involving 37 patients who had persisting fatigue but no severe 
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depression or anemia after completing chemotherapy an average of more than two 
years previously. 
These data are insufficient to conclude that there is benefit from acupuncture. Further 
studies in larger cohorts are needed.
Pharmacologic management — Although empiric administration of psycho 
stimulants in patients with cancer-related fatigue has been reported to improve 
symptoms in open-label studies, double-blinded trials are needed to prove benefit in 
view of the subjective nature of fatigue and the demonstrated therapeutic effect from 
placebo in at least one double-blind trial .
Methylphenidate — Methylphenidate, a central nervous system stimulant that is 
structurally related to amphetamines, has a short half-life and a rapid onset of action. 
Open-label studies suggested an improvement in symptoms of fatigue, sedation, and 
pain48.
Modafinil — Modafinil, a non-amphetamine "wake-promoting agent", is used for the 
treatment of narcolepsy. Limited experience in cancer patients suggests that modafinil 
is well tolerated and may be a useful treatment for cancer-related fatigue, particularly 
in patients with severe fatigue. The benefits of modafinil in the treatment of cancer-
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related fatigue can be illustrated by the following data: In a pilot study presented at 
the ASCO meeting in June 2006, 30 patients with primary brain tumors complicated 
by neurobehavioral dysfunction and fatigue were randomly assigned to modafinil at 
either 200 or 400 mg/day for three weeks49. This was followed by a washout period of 
one week and open label extension of treatment for an additional eight weeks. 
Analysis of neurobehavioral function and fatigue demonstrated improvement across 
cognitive, mood, and fatigue outcome measures, with the maximum benefit at eight 
weeks after initiation of treatment. In a preliminary report at the 2008 ASCO meeting, 
patients receiving modafinil rather than placebo had a significant overall benefit from 
the drug as assessed by self-report of symptoms during cycle four of therapy; 
however, the benefit seemed to be limited to those with severe fatigue (>6 on a 10-
point scale). Modafinil did not improve depression, reinforcing the view that 
depression and cancer-related fatigue are not linked. 
Starting doses of modafinil are usually 100 to 200 mg in the morning and again at 
noon. The maximum daily dose is 400 mg.
Antidepressants — At least three placebo-controlled, randomized trials in patients 
undergoing cancer treatment have failed to demonstrate any improvement in fatigue in 
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patients randomly assigned to receive an antidepressant (paroxetine, sertraline), 
despite improvement in depressive symptoms.
However, antidepressants may be helpful when a patient has both fatigue and 
depression. For patients who also have insomnia, nortriptyline or amitriptyline are 
good choices. Case reports suggest efficacy for bupropion in patients with chronic 
fatigue syndrome, but no data are available in patients with cancer-related fatigue.
Steroids — Anecdotal experience suggests that corticosteroids may be beneficial for 
some patients with cancer-related fatigue50; however, side effects limit their long-term 
use. Steroids may be most helpful for patients with cancer-related fatigue who are in 
the terminal phase of advanced cancer. Dose management is improtant, as this class of 
drugs may induce insomnia and/or behavioral changes.
Donepezil — Pilot studies with donepezil, a selective acetylcholinesterase inhibitor, 
suggested that this approach might be useful in patients with cancer-related fatigue. 
However, a randomized trial did not show any benefit compared to placebo51.
Multivitamins — Multivitamins have been assessed in a small randomized trial, in an 
effort to ameliorate the fatigue in women receiving radiation therapy. No benefit could 
be ascribed to the use of multivitamins.
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As we can see from the above discussion there is no one single or for that matter 
multi-dimensional treatment modality that is effective in treating the Cancer Related 
Fatigue.
Perhaps the answers will be found only when effective questions are asked.
This study was an effort to prove the prevalence of this debilitating symptom that 
every cancer patient complains of during the course of the disease.
We sincerely hope that the effective methods like the Fatigue scale & the FACT-G 
questionnaires find their way into daily practice so that Fatigue can be screened 
effectively & every effort can be made to decrease the fatigue & improve the Quality 
of life in Cancer Patients.
This study concludes that Cancer Related Fatigue is real & it effects Quality of Life of 
patients , so the vital question is 
Will improvement in quality of life (QOL) impact fatigue in patients receiving 
treatment for cancer?
The answer to the above question  needs to be studied further.
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CONCLUSION                            
Fatigue prevalence – In this study 100% of the patients studied had fatigue be it 
either mild, moderate or severe. While other studies have had ranges from 65-
90%.One of the reasons for this variation could be that the patients in this study 
were all from low socio-economic group which makes it that much harder for 
them to have nutritious wholesome meal for 3/day.
Cancer Related Fatigue affected all areas of patient’s life. Cancer related fatigue 
effected the time taken by the patients to attain normal productive life
Cancer Related Fatigue peaked at 4-5 weeks of treatment .As observed in this 
study & review of the previous literature suggests that the Cancer related 
fatigue peaked during 4th- 5th week of the treatment .The reason for this needs to 
be further evaluated.
Cancer Related Fatigue reduces the Quality of Life in patients .Cancer related 
fatigue effected every aspect of the patients life. It had a negative effect on the 
Emotional, Functional, Physical & social well being of the patients.
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Cancer related fatigue never reached pretreatment level scores. In this study 
none of the patients ever reported to reach the pre-treatment levels of fatigue 
even at 2 months of follow up.
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APPENDIX I  - ETHICAL COMMITTEE APPROVAL
APPENDIX II – CONSENT  FORM 
APPENDIX  III
APPENDIX IV – LICENCE TO USE FACT-G FOR THIS STUDY
APPENDIX V 
APPENDIX  VI  -  PHYHSICAL WELL BEING
APPENDIX VII – FACT G  - SOCIAL WELL BEING 
APPENDIX VIII – FACT G – EMOTIONAL WELL BEING
APPENDIX I X  - FACT –G  - FUNCTIONAL WELL BEING
APPENDIX  XI  - FACT-G Scoring Guidelines (Version 4)
Instructions:* 1. Record answers in "item response" column. If missing, mark with an X
   2. Perform reversals as indicated, and sum individual items to obtain a score.
3. Multiply the sum of the item scores by the number of items in the subscale, then divide by the  
    number of items answered.  This produces the subscale score.
4. Add subscale scores to derive total FACT-G score. The higher the score, the better the QOL.
Subscale   Item Code    Reverse item?       Item response        Item Score 
PHYSICAL GP1 4 - ________ =________
WELLBEING GP2 4 - ________ =________
   (PWB) GP3 4 - ________ =________
      GP4 4 - ________ =________
      GP5 4 - ________ =________
      GP6 4 - ________ =________
      GP7 4 - ________ =________
              Sum individual item scores: ________  
                      Multiply by 7: ________
             Divide by number of items answered: ________=PWB subscale 
score
SOCIAL/FAMILY GS1 0 + ________ =________
WELLBEING GS2 0 + ________ =________
    (SWB) GS3 0 + ________ =________
      GS4 0 + ________ =________
      GS5 0 + ________ =________
   GS6 0 + ________ =________
      GS7 0 + ________ =________
Score range: 0-28
Score range: 0-28
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             Sum individual item scores: ________  
                     Multiply by 7: ________
            Divide by number of items answered: ________=SWB subscale 
score
EMOTIONAL GE1 4 - ________ =________
WELLBEING GE2 0 + ________ =________
    (EWB) GE3 4 - ________ =________
      GE4 4 - ________ =________
     GE5 4 - ________ =________
GE6 4 - ________ =________
             Sum individual item scores: ________  
                     Multiply by 6: ________
            Divide by number of items answered: ________=EWB subscale 
score
FUNCTIONAL  GF1 0 + ________ =________
WELL-BEING GF2 0 + ________ =________
     (FWB) GF3 0 + ________ =________
      GF4 0 + ________ =________
      GF5 0 + ________ =________
      GF6 0 + ________ =________
      GF7 0 + ________ =________
             Sum individual item scores: ________  
                     Multiply by 7: ________
            Divide by number of items answered: ________=FWB subscale 
score
TOTAL SCORE:
       __________ + __________ + __________ + __________=________=FACT-G 
Total score
      (PWB score)    (SWB score)   (EWB score)  (FWB score)
*For additional guidelines please refer to the Administration and Scoring Guidelines in the manual or at 
www.facit.org.
Score range: 0-24
Score range: 0-28
Score range: 0-108
